+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07021989

Pembrolizumab with GVD Chemotherapy and ctDNA-Guided Consolidation for Relapsed or Refractory Classic Hodgkin Lymphoma A Multicenter Phase 2 Study by the University of California Hematologic Malignancies Consortium

Led by Michael Spinner, MD · Updated on 2026-10-20

38

Participants Needed

6

Research Sites

243 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of pembrolizumab pembro, gemcitabine, vinorelbine, and liposomal doxorubicin GVD in patients with relapsed or refractory classic Hodgkin lymphoma cHL. This phase II, multicenter, open-label study aims to determine the complete response rate using both imaging and circulating tumor DNA ctDNA to assess minimal residual disease MRD and treatment response. The study also evaluates progression-free and overall survival, adverse events, and quality of life over time, with long-term follow-up for up to 5 years. Participants receive two 21-day cycles of pembrolizumab intravenously on day 1, alongside gemcitabine, vinorelbine, and liposomal doxorubicin administered intravenously on days 1 and 8 of each cycle. Pegfilgrastim is given for supportive care during each cycle. After two cycles, response is assessed by PETCT imaging and ctDNA testing using the Foresight CLARITY LDT platform. Based on response, participants may continue with additional pembrolizumab and GVD cycles, undergo non-transplant consolidation with pembrolizumab andor involved-site radiotherapy ISRT, or switch to salvage therapy and autologous stem cell transplant ASCT. Throughout the study, participants undergo periodic imaging and blood tests to monitor disease status, including PETCT scans and advanced ctDNA assessments. Patient-reported outcomes and quality of life are measured via standardized questionnaires. Safety monitoring includes tracking adverse events and immune-related effects. Participants are followed for up to five years to evaluate long-term outcomes and treatment effects, with the primary outcome focusing on complete response rate within four cycles of therapy.

CONDITIONS

Brief Title

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Research Team

U

UCSF Hematopoietic Malignancies Clinical Trial Recruitment

N

Nickole Criner

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here